ICE inhibitors for the treatment of autoinflammatory diseases

Details for Australian Patent Application No. 2005249503 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Randle, John C. R.

Agent Cullens

Pub. Number AU-B-2005249503

PCT Pub. Number WO2005/117846

Priority 60/519,055 10.11.03 US

Parent 2004290413

Filing date 27 May 2005

Wipo publication date 15 December 2005

Acceptance publication date 25 August 2011

International Classifications

A61K 31/00 (2006.01)

A61K 31/401 (2006.01) - Proline

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

C07D 207/16 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

21 December 2006 PCT application entered the National Phase

  PCT publication WO2005/117846 Priority application(s): WO2005/117846

25 August 2011 Application Accepted

  Published as AU-B-2005249503

22 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005249504-Use of IL-17 in the treatment of fertilityrelated disorders

2005249502-Injectable pharmaceutical suspension comprising posaconazole